Confirmed Sponsors

Click the logo to access the sponsor's page.

Main Partner
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.
About Novartis Novartis is reimagining medicine to improve people’s lives. We use innovative science and digital technologies to create transformative treatments. Novartis products reach more than 800 million people globally and we are finding innovative ways to expand access to our medicines. About 109,000 people of more than 145 nationalities work at Novartis. www.novartis.com.
lnjeq was founded by a team of clinicians and technology experts who identified a solution for making blind spinal punctures more precise and safer. Thanks to their interdisciplinary backgrounds, they knew that various tissues conduct electricity in a slightly different way. This electrical conductivity is analyzed with lnjeq IQ-Tip® analyzer. When the lnjeq IQ-Tip® spinal needle tip reaches cerebrospinal fluid, the system alerts the physician with an audio signal, also the analyzer display indicates high conductivity. Today lnjeq is proceeding with CE certification through Notified Body TUV SUD, aiming for European market in accordance with the MDR before summer 2021.
Nova Laboratories
Nova Laboratories is a pioneering pharmaceutical company and leading contract manufacturer. We excel at delivering innovative technical solutions to tackle rare and global diseases. When founded more than 26 years ago, our expertise consisted of compounding sterile and non-sterile specials for UK hospitals and community pharmacies. We are now one of the most innovative and advanced global suppliers of medicines and services including aseptic contract manufacturing, clinical trials, live biologics and stabilisation technologies with our own branded licensed drugs portfolio. Our heritage and vision is built around our investment in leading technical innovations in manufacturing, which enable us and our customers to address global unmet clinical needs.
ERYTECH is a clinical-stage biopharmaceutical company developing innovative red blood cell-based therapeutics for severe forms of cancer. Leveraging its proprietary ERYCAPS® platform, which uses a novel technology to encapsulate drug substances inside red blood cells, ERYTECH is developing a pipeline of product candidates for patients with high unmet medical needs. ERYTECH’s primary focus is developing product candidates that target the altered metabolism of cancer cells by depriving them of amino acids necessary for their growth and survival. The Company’s lead product candidate, eryaspase, which consists of L-asparaginase encapsulated inside donor-derived red blood cells, targets the cancer cells’ altered metabolism.